D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC--Outcomes based on chemotherapy subsets.
Heather A. Wakelee,Suzanne E. Dahlberg,Steven M. Keller,William Tester,David R. Gandara,Stephen L. Graziano,Alex A. Adjei,Natasha B. Leighl,Charles A. Butts,Seena C. Aisner,Jan M. Rothman,Jyoti D. Patel,Mark D. Sborov,Raymond S. McDermott,Roman Perez-Soler,Anne M. Traynor,Tracey L. Evans,Leora Horn,Suresh S. Ramalingam,Joan H. Schiller +19 more
TL;DR: The E1505 trial as mentioned in this paper showed that the addition of bevacizumab (B) to adjuvant chemo failed to improve the primary endpoint of overall survival (OS HR=0.99; 95% CI: 0.82-1.15, p= 0.89).
Journal ArticleDOI
Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.
TL;DR: Research efforts continue to focus on identifying molecular markers and corresponding clinical features that will allow physicians to individualize patients' therapy, and multiple novel agents are being investigated as single agents or in combination with approved second-line therapies.
Journal ArticleDOI
1296OClinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study
Shirish M. Gadgeel,Marcin Kowanetz,Wei Zou,Fred R. Hirsch,Keith M. Kerr,David R. Gandara,Fabrice Barlesi,K. Park,Mark McCleland,Hartmut Koeppen,Marcus Ballinger,Alan Sandler,Priti S. Hegde,Achim Rittmeyer +13 more
Journal ArticleDOI
Enhancement of Radiation Cytotoxicity by UCN-01 in Non-small Cell Lung Carcinoma Cells
Philip C. Mack,A. Jones,Matthew H. Gustafsson,David R. Gandara,Paul H. Gumerlock,Zelanna Goldberg +5 more
TL;DR: These studies demonstrated that radiation plus UCN-01 was more effective in cells with diminished TP53 activity, associated with a reduced G1 checkpoint arrest, and indicate that simultaneous elimination of multiple DNA damage-induced checkpoints in G1, S and G2 may enhance the effects of radiation and that drug scheduling may have an impact on clinical efficacy.
Journal ArticleDOI
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: A california cancer consortium trial
Primo N. Lara,Primo N. Lara,Jeff Longmate,Karen L. Reckamp,Barbara J. Gitlitz,Athanassios Argiris,Suresh S. Ramalingam,Chandra P. Belani,P. C. Mack,Derick H Lau,Derick H Lau,Mariana Koczywas,John J. Wright,Frances A. Shepherd,Natasha B. Leighl,David R. Gandara +15 more
TL;DR: Docetaxel plus bortezomib given sequentially or concurrently has similar RR and PFS and Median survival in the SEQ arm exceeds published survival estimates for either agent alone or in combination.